novartis

During the first half of the year, the revenues of the Catalan multinational pharmaceutical company Grifols rose by 16.7% to €1.61 bilion, 75% of which came from the Bioscience division and 18% from Diagnostic. Compared to the first quarter, the proportion of total sales generated by each of the group’s divisions remains unchanged after the acquisition of Novartis' diagnostic business. The world´s third-largest blood-derivate product maker, Grifols obtained a net profit of €224.8 million, 23% more compared with the same period last year, as reported by the company to the Spanish Stock Exchange Authority (CNMV). These positive figures were achieved due to the maintenance of financial costs, made possible by improved financial conditions, despite having increased debt in absolute terms.

The Catalan pharmaceutical company Grífols, based in Greater Barcelona, has bought part of the diagnostics unit of Swiss multinational Novartis for $1,675 million. Grífols has acquired products and ‘in vitro’ technology applied to diagnoses in the fields of blood transfusion and immunology, along with a production plant in California and offices in the US, Switzerland and Hong Kong. With the acquisition, the Grífols Diagnostic Division will represent $1 billion, 20% of the Catalan group’s total revenues. Grífols is the world’s third largest company in the production of blood-plasma derivatives. In the first half of 2013, Grífols registered a profit of €182.2 million, an increase of 36.9% on the same period of 2012.